

SUCCESSION IN THE ROLE OF GROUP CHIEF FINANCIAL OFFICER OF DIASORIN

ALBERTO DONATI APPOINTED NEW GROUP CHIEF FINANCIAL OFFICER

Saluggia, Italy – January 23, 2026 – Diasorin S.p.A. (FTSE MIB: DIA) ("**Diasorin**" or the "**Company**") announces that Mr. Piergiorgio Pedron, *Group Chief Financial Officer*, will leave the Diasorin Group with effect from March 31, 2026 to pursue new professional opportunities.

The Company would like to thank Mr. Pedron for his significant contribution to the evolution of the Group in an important phase of growth and transformation, wishing him the best for future professional challenges.

To date, Mr. Pedron does not own any equity interests in the Company and its subsidiaries.

At the same time, Diasorin announces that the role of Group Chief Financial Officer will be held, as of April 1, 2026, by Mr. Alberto Donati, who has been working for over 14 years in the Diasorin Group with positions of increasing responsibility both in complex international markets and at the corporate level during which he has developed a deep knowledge of the business, of the Company's financial and governance processes and dialogue with top-level stakeholders.

The appointment guarantees strategic continuity, management solidity and strong consistency with the company's values.

It should be noted that to date Mr. Donati owns 796 shares of the Company.

ABOUT DIASORIN

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations

riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst

eugenia.ragazzo@diasorin.com